Open AccessAnalysis of the Financial Impact of Using Cangrelor on the Safety and Efficacy Outcomes in Patients Undergoing Percutaneous Coronary Intervention in Whom Oral Therapy with P2Y12 Inhibitors is Not Feasible or Desirable, in Spain
Author(s) -
Irene Lizano-Díez,
S. Paz
Publication year - 2021
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s290377
Subject(s) - cangrelor , medicine , p2y12 , percutaneous coronary intervention , clopidogrel , ticagrelor , conventional pci , prasugrel , cardiology , coronary artery disease , clinical trial , intensive care medicine , aspirin , myocardial infarction
Cangrelor is an intravenous, direct-acting, reversible P2Y 12 inhibitor indicated for the reduction of thrombotic cardiovascular events in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) in whom oral P2Y 12 inhibitors are not feasible or desirable. The objective was to assess the financial impact of introducing cangrelor into the hospital formulary in Spain.